Dr. Rajiv Bahl, the Director General of the Indian Council of Medical Research (ICMR), shared insights into new projects and accomplishments in public health during the 19th International Conference of Drug Regulatory Authorities (ICDRA) INDIA-2024. He emphasized a breakthrough in tuberculosis (TB) diagnosis through an innovative handheld X-ray device aimed at enhancing early detection and treatment. This new technology, developed collaboratively with IIT Kanpur, will be available at a significantly lower price, making it more accessible for screenings in communities, especially for vulnerable populations.
In addition to the TB advancements, Dr. Bahl announced the creation of three testing kits for Mpox, with local companies now producing these essential tools. The ICMR’s commitment to improving public health is evident, especially considering that more than a million individuals in India are impacted by sickle cell disease, which ranks as the second largest prevalence globally. To address this, Prime Minister Narendra Modi initiated the National Sickle Cell Anaemia Elimination Mission, which aims to eradicate this public health challenge by 2047.
The ICMR has been proactive in its efforts, recently organizing a collaborative session with medical professionals and scientists across the nation. Dr. Bahl reported a significant achievement with the development of 18 low-cost tests for sickle cell anemia, reducing the price per test from $5 to just $0.36.
Addressing the issue of dengue fever, which has claimed numerous lives in India, Dr. Bahl mentioned that a vaccine could be on the horizon. Currently, the ICMR is conducting phase three clinical trials for a dengue vaccine, with results expected in about a year. If proven safe and effective, this vaccine will be a pivotal addition to India’s public health arsenal. Through these initiatives, the ICMR demonstrates its dedication to improving health outcomes and enhancing the country’s overall public health infrastructure.
